Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2001
Clinical TrialCombination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis.
The effects of combined treatment with cyclophosphamide (CTX) and interferon-beta (IFN-beta) are described in selected patients with "rapidly transitional" multiple sclerosis. This form of multiple sclerosis is extremely active with very frequent and severe attacks which produce a dramatic increase on the expanded disability status scale (EDSS). ⋯ This particular group of patients benefited by combining cyclophosphamide and IFN-beta. The possibility is considered of carrying out further studies to test the efficacy of the association between the two drugs for patients who are not responsive to IFN-beta or other active disease modifying therapies.
-
J. Neurol. Neurosurg. Psychiatr. · Sep 2001
The SF-36 in multiple sclerosis: why basic assumptions must be tested.
To evaluate, in people with multiple sclerosis, two psychometric assumptions that must be satisfied for valid use of the medical outcomes study 36-item short form health survey (SF-36): the data are of high quality and, it is legitimate to generate scores for eight scales and two summary measures using the standard algorithms. ⋯ When using the SF-36 as a health measure in multiple sclerosis summary scores should be reported with caution.